Patents by Inventor Andrew Hendifar

Andrew Hendifar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INTERLEUKIN-1 INHIBITION FOR COMBINATION TREATMENT OF PANCREATIC CANCER CACHEXIA
    Publication number: 20240002496
    Abstract: A composition for IL-1 inhibition in combination with cancer therapies (e.g., chemotherapeutics including chemotherapy protective drugs) is provided for use in treating pancreatic cancer cachexia in patients, so as to reduce weight loss and improve the quality of life and survival of the patients. In one embodiment, the IL-1 inhibitor is an antibody, such as bermekimab, anakinra, canakinumab, gevokizumab, or rilonacept, administered simultaneously or sequentially with iritenocan, 5-fluorouracil and folinic acid to a pancreatic cancer patient.
    Type: Application
    Filed: September 11, 2023
    Publication date: January 4, 2024
    Applicant: Cedars-Sinai Medical Center
    Inventor: Andrew Hendifar
  • Interleukin-1 inhibition for combination treatment of pancreatic cancer cachexia
    Patent number: 11795217
    Abstract: A composition for IL-1 inhibition in combination with cancer therapies (e.g., chemotherapeutics including chemotherapy protective drugs) is provided for use in treating pancreatic cancer cachexia in patients, so as to reduce weight loss and improve the quality of life and survival of the patients. In one embodiment, the IL-1 inhibitor is an antibody, such as bermekimab, anakinra, canakinumab, gevokizumab, or rilonacept, administered simultaneously or sequentially with iritenocan, 5-fluorouracil and folinic acid to a pancreatic cancer patient.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: October 24, 2023
    Assignee: Cedars-Sinai Medical Center
    Inventor: Andrew Hendifar
  • GLUTAMINE AS AN ANTICANCER THERAPY IN SOLID TUMORS
    Publication number: 20230277490
    Abstract: The present invention provides for methods of treating solid tumors, particularly, KRas mutated solid tumors and KRas mutated pancreatic cancer. The method includes administering glutamine alone or in combination with an anti-cancer agent; for example, gemcitabine or nab-paclitaxel. The method includes administering glutamine and radiotherapy, or glutamine and immunotherapy to treat these cancers.
    Type: Application
    Filed: July 30, 2021
    Publication date: September 7, 2023
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Jun Gong, Andrew Hendifar, Neil Bhowmick, Hayato Muranaka
  • METHOD OF TREATING PANCREATIC CANCER
    Publication number: 20230060581
    Abstract: The present invention provides for a method to treat pancreatic cancer. In various embodiments the method provides for administering one or more MAPK one or more MAPK pathway inhibitors to the subject, wherein the subject has a mutation in one or more genes in the MAPK signaling pathway.
    Type: Application
    Filed: February 9, 2021
    Publication date: March 2, 2023
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventor: Andrew Hendifar
  • INTERLEUKIN-1 INHIBITION FOR COMBINATION TREATMENT OF PANCREATIC CANCER CACHEXIA
    Publication number: 20210230268
    Abstract: A composition for IL-1 inhibition in combination with cancer therapies (e.g., chemotherapeutics including chemotherapy protective drugs) is provided for use in treating pancreatic cancer cachexia in patients, so as to reduce weight loss and improve the quality of life and survival of the patients. In one embodiment, the IL-1 inhibitor is an antibody, such as bermekimab, anakinra, canakinumab, gevokizumab, or rilonacept, administered simultaneously or sequentially with iritenocan, 5-fluorouracil and folinic acid to a pancreatic cancer patient.
    Type: Application
    Filed: March 19, 2021
    Publication date: July 29, 2021
    Applicant: Cedars-Sinai Medical Center
    Inventor: Andrew Hendifar
  • Interleukin-1 inhibition for combination treatment of pancreatic cancer
    Patent number: 10975146
    Abstract: A composition for IL-1 inhibition in combination with cancer therapies (e.g., chemotherapeutics including chemotherapy protective drugs) is provided for use in treating pancreatic cancer cachexia in patients, so as to reduce weight loss and improve the quality of life and survival of the patients. In one embodiment, the IL-1 inhibitor is an antibody, such as bermekimab, anakinra, canakinumab, gevokizumab, or rilonacept, administered simultaneously or sequentially with iritenocan, 5-fluorouracil and folinic acid to a pancreatic cancer patient.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: April 13, 2021
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventor: Andrew Hendifar
  • INTERLEUKIN-1 INHIBITION FOR COMBINATION TREATMENT OF PANCREATIC CANCER CACHEXIA
    Publication number: 20200002412
    Abstract: A composition for IL-1 inhibition in combination with cancer therapies (e.g., chemotherapeutics including chemotherapy protective drugs) is provided for use in treating pancreatic cancer cachexia in patients, so as to reduce weight loss and improve the quality of life and survival of the patients. In one embodiment, the IL-1 inhibitor is an antibody, such as bermekimab, anakinra, canakinumab, gevokizumab, or rilonacept, administered simultaneously or sequentially with iritenocan, 5-fluorouracil and folinic acid to a pancreatic cancer patient.
    Type: Application
    Filed: June 28, 2019
    Publication date: January 2, 2020
    Applicant: Cedars-Sinai Medical Center
    Inventor: Andrew Hendifar